PMID- 22014037
OWN - NLM
STAT- MEDLINE
DCOM- 20120123
LR  - 20220318
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 11
DP  - 2011 Oct 20
TI  - Clinical implication of HLA class I expression in breast cancer.
PG  - 454
LID - 10.1186/1471-2407-11-454 [doi]
AB  - BACKGROUND: Human leukocyte antigen (HLA)-class I molecules on tumor cells have 
      been regarded as crucial sites where cytotoxic T lymphocytes (CTL) can recognize 
      tumor-specific antigens and are strongly associated with anti-tumor activity. 
      However, the clinical impact of HLA class I expression in breast cancer has not 
      been clarified. METHODS: A total of 212 breast cancer patients who received 
      curative surgery from 1993 to 2003 were enrolled in the current study. HLA class 
      I expression was examined immunohistochemically using an anti-HLA class I 
      monoclonal antibody. The correlation between HLA class I positivity and clinical 
      factors was analyzed. RESULTS: The downregulation of HLA class I expression in 
      breast cancer was observed in 69 patients (32.5%). HLA class I downregulation was 
      significantly associated with nodal involvement (p < 0.05), TNM stage (p < 0.05), 
      lymphatic invasion (p < 0.01), and venous invasion (p < 0.05). Patients with 
      preserved HLA class I had significantly better disease-free interval (DFI) than 
      those with loss of HLA class I (p < 0.05). However, in multivariable analysis, 
      HLA class I was not selected as one of the independent prognostic factors of 
      disease-free interval. CONCLUSION: The examination of HLA class I expression is 
      useful for the prediction of tumor progression and recurrent risk of breast 
      cancer via the antitumor immune system.
FAU - Kaneko, Koichi
AU  - Kaneko K
AD  - Department of Surgical Oncology, Breast and Endocrine Surgery, Kagoshima 
      University School of Medicine, Japan.
FAU - Ishigami, Sumiya
AU  - Ishigami S
FAU - Kijima, Yuko
AU  - Kijima Y
FAU - Funasako, Yawara
AU  - Funasako Y
FAU - Hirata, Munetsugu
AU  - Hirata M
FAU - Okumura, Hiroshi
AU  - Okumura H
FAU - Shinchi, Hiroyuki
AU  - Shinchi H
FAU - Koriyama, Chihaya
AU  - Koriyama C
FAU - Ueno, Shinichi
AU  - Ueno S
FAU - Yoshinaka, Heiji
AU  - Yoshinaka H
FAU - Natsugoe, Shoji
AU  - Natsugoe S
LA  - eng
PT  - Journal Article
DEP - 20111020
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal
MH  - Biomarkers, Tumor/metabolism
MH  - Breast Neoplasms/*immunology/pathology/surgery
MH  - Disease-Free Survival
MH  - Down-Regulation
MH  - Female
MH  - Histocompatibility Antigens Class I/*metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - Lymph Nodes/pathology
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Young Adult
PMC - PMC3214195
EDAT- 2011/10/22 06:00
MHDA- 2012/01/24 06:00
PMCR- 2011/10/20
CRDT- 2011/10/22 06:00
PHST- 2011/01/10 00:00 [received]
PHST- 2011/10/20 00:00 [accepted]
PHST- 2011/10/22 06:00 [entrez]
PHST- 2011/10/22 06:00 [pubmed]
PHST- 2012/01/24 06:00 [medline]
PHST- 2011/10/20 00:00 [pmc-release]
AID - 1471-2407-11-454 [pii]
AID - 10.1186/1471-2407-11-454 [doi]
PST - epublish
SO  - BMC Cancer. 2011 Oct 20;11:454. doi: 10.1186/1471-2407-11-454.